Quarterly report pursuant to Section 13 or 15(d)

Organization, Description of Business and Basis of Presentation - Business Disposals - Discontinuing Operations (Details)

v3.20.1
Organization, Description of Business and Basis of Presentation - Business Disposals - Discontinuing Operations (Details) - USD ($)
3 Months Ended
Oct. 24, 2019
Jul. 15, 2019
Jul. 05, 2019
Mar. 31, 2020
Mar. 31, 2019
Dec. 31, 2019
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]            
Excess consideration note matured amount $ 6,000,000          
Interest paid       $ 0 $ 1,110,000  
Net due to related party       1,300,000    
Earn-Out from siParadigm, current portion       772,000   $ 747,000
Earn-Out from siParadigm, noncurrent portion       201,000    
BioPharma Disposal            
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]            
Gross consideration $ 153,000 $ 23,500,000        
Closing adjustments   2,000,000        
Promissory note receivable   7,700,000        
Cash received from transaction   $ 2,300,000        
Interest rate 6.00%          
Interest paid $ 24,000          
Net worth adjustment 775,000          
Security for indemnification obligations $ 735,000          
PFG | Secured Debt            
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]            
Term note, principal balance       6,000,000    
siParadigm            
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]            
Due to affiliate, current       573,000   566,000
Due to affiliate, noncurrent       119,000   252,000
Transition Services Agreement | BioPharma Disposal            
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]            
Related party shares services       102,000    
Reimbursement due       $ 102,000    
Clinical Agreement            
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]            
Cash consideration received, total     $ 747,000      
Cash consideration received for equipment     45,000      
Payments on Advance from NovellusDx, Ltd.     1,000,000      
Supplier invoices paid directly to related party     177,000      
Adjustment     11,000      
Transaction costs     $ 110,000      
Term of contract     24 months      
Period of service     12 months      
Non-compete term     3 years      
Discontinuing Operations | Convertible Note            
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]            
Interest expense, debt         $ 786,000  
Excess Consideration Note            
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]            
Fair value           $ 888,000